Instil Bio, Inc. (TIL): Shareholders' Equity
$113.87M
As of 2025-12-31
$107.38M
As of 2026-06-30
-32.1%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $113.87M | -32.8% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $169.44M | -25.0% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $225.83M | -37.9% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $363.61M | -34.5% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $555.20M | n/m | 2023-03-31, Balance as of period end |
| 2020-12-31 | -$39.60M | n/a | 2022-03-07, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | 2025-12-31 | $113.87M | -32.8% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $196.41M | +17.5% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $103.87M | -63.8% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $196.79M | +57.1% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $158.60M | -32.5% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $167.71M | -38.5% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $27.29M | -79.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $87.80M | +49.0% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $158.94M | -1.5% |
Compare TIL, TARA, NMRA, CMPX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗